当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Abstract：

:In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and repressed RelA DNA binding by trapping the p50 subunit. Reciprocally, RelA activation repressed RelB activity by increasing expression of its inhibitor p100. To search for such reciprocal inhibition at the transcriptional level, we studied gene expression profiles of our RelA and RelB regulatable cellular models. Ten RelA-induced genes and one RelB-regulated gene, ARNTL2, were repressed by RelB and RelA, respectively. Apart from this gene, RelB signature was included in that of RelA Functional groups of RelA-regulated genes were for control of energy metabolism, genetic instability, protection against apoptosis, cell cycle and immune response. Additional functions coregulated by RelA and/or RelB were autophagy and plasma cell differentiation. Altogether, these results demonstrate a cross-inhibition between RelA and RelB and suggest that, in fine, RelB was subordinated to RelA. In the view of future drug development, RelA appeared to be pivotal in both classical and alternative activation pathways, at least in EBV-transformed B cells.

journal_name

Leukemia

journal_title

Leukemia

authors

Chanut A,Duguet F,Marfak A,David A,Petit B,Parrens M,Durand-Panteix S,Boulin-Deveza M,Gachard N,Youlyouz-Marfak I,Bordessoule D,Feuillard J,Faumont N

doi

10.1038/leu.2013.274

subject

Has Abstract

pub_date

2014-04-01 00:00:00

pages

871-9

issue

4

eissn

0887-6924

issn

1476-5551

pii

leu2013274

journal_volume

28

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome.

    abstract：:A 32-year-old white woman was admitted with a diagnosis of T lymphoblastic lymphoma and a bone marrow and peripheral blood cytology that was suggestive of a myeloproliferative syndrome (MPS). In addition, islets of myeloid precursors were found in the lymph node where the lymphoma had been diagnosed. Cytogenetic exami...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Behringer D,Schaefer HE,Kunzmann R,Mertelsmann R,Dölken G

    更新日期：1995-06-01 00:00:00

  • Genomic approaches to small molecule discovery.

    abstract：:With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.29

    authors： Stegmaier K

    更新日期：2009-07-01 00:00:00

  • The retinoic acid alpha receptor gene is frequently disrupted in its 5' part in Chinese patients with acute promyelocytic leukemia.

    abstract：:The t(15;17)(q22;q11-q21) translocation, a hallmark for acute promyelocytic leukemia (APL), has recently been shown to disrupt the retinoic acid-alpha receptor (RARA) gene localized on band 17q21. Leukemic cell DNAs from 16 Chinese patients with APL were analysed by Southern blot hybridization with probes covering the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Chen Z,Chen SJ,Tong JH,Zhu YJ,Huang ME,Wang WC,Wu Y,Sun GL,Wang ZY,Larsen CJ

    更新日期：1991-04-01 00:00:00

  • Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.

    abstract：:Monoclonal antibody QBEND10 is reactive with the CD34 antigen in aldehyde-fixed, decalcified, paraffin-embedded bone marrow biopsies. In normal bone marrow it stained endothelial cells lining arterioles and capillaries, sinusoidal (littoral) cells and 0.89% of all haemopoietic cells. QBEND10+ mononuclear cells were se...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Soligo D,Delia D,Oriani A,Cattoretti G,Orazi A,Bertolli V,Quirici N,Deliliers GL

    更新日期：1991-12-01 00:00:00

  • Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

    abstract：:Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with acquired imatinib resistance, but their role in primary resistance is uncertain. Using highly sensitive ligat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.5

    authors： Pfeifer H,Lange T,Wystub S,Wassmann B,Maier J,Binckebanck A,Giagounidis A,Stelljes M,Schmalzing M,Dührsen U,Wunderle L,Serve H,Brück P,Schmidt A,Hoelzer D,Ottmann OG

    更新日期：2012-07-01 00:00:00

  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.

    abstract：:A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelogenous leukemia. One hundred and thirty-one patients stratified by age...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Vogler WR,McCarley DL,Stagg M,Bartolucci AA,Moore J,Martelo O,Omura GA

    更新日期：1994-11-01 00:00:00

  • The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells.

    abstract：:The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Fenstermaker RA,Capala J,Barth RF,Hujer A,Kung HJ,Kaetzel DM Jr

    更新日期：1995-10-01 00:00:00

  • Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.

    abstract：:Allogeneic stem cell transplantation for acute myeloid leukemia (AML) using reduced-intensity conditioning (RIC) is based on the strategy of attaining donor cell engraftment with immunosuppressive agents. This approach, which relies predominantly on donor effector cells for anti-leukemic or graft-versus-leukemia effec...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404328

    authors： Lazarus HM,Rowe JM

    更新日期：2006-10-01 00:00:00

  • Polyclonal expansion of T-cell receptor-gamma delta+ T lymphocytes associated with neutropenia and thrombocytopenia.

    abstract：:A patient with large granular lymphocyte (LGL) expansion (T-gamma lymphocytosis), neutropenia and thrombocytopenia was studied longitudinally. Analysis of peripheral blood mononuclear cells (PBMC) demonstrated an unusual large proportion of CD3+ T-lymphocytes expressing a gamma delta T-cell receptor (TcR-gamma delta)....

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： van Oostveen JW,Breit TM,de Wolf JT,Brandt RM,Smit JW,van Dongen JJ,Borst J,Melief CJ

    更新日期：1992-05-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405087

    authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期：2008-04-01 00:00:00

  • Characterization of acute myeloid leukemia (AML) coexpressing lymphoid markers: different biologic features between T-cell antigen positive and B-cell antigen positive AML.

    abstract：:The clinical and biologic characteristics of acute myeloid leukemia (AML) with coexpression of lymphoid-associated antigens (Lym+ AML) were studied from 39 cases who represented 24% of 161 newly diagnosed de novo AML. Twenty-seven cases (16.8%) were positive for the expression of T-cell markers (T+ AML) and 12 (7.5%) ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Tien HF,Wang CH,Chen YC,Shen MC,Lin DT,Lin KH

    更新日期：1993-05-01 00:00:00

  • Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

    abstract：:Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401331

    authors： Broxterman HJ,Sonneveld P,Pieters R,Lankelma J,Eekman CA,Loonen AH,Schoester M,Ossenkoppele GJ,Löwenberg B,Pinedo HM,Schuurhuis GJ

    更新日期：1999-02-01 00:00:00

  • Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.

    abstract：:Acute myelogenous leukemia (AML) remains a deadly disease for most adult patients, due primarily to the emergence of chemoresistant cells. Defects in apoptosis pathways make important contributions to chemoresistance, suggesting a need to restore apoptosis sensitivity or to identify alternative pathways for apoptosis ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403112

    authors： Suh WS,Kim YS,Schimmer AD,Kitada S,Minden M,Andreeff M,Suh N,Sporn M,Reed JC

    更新日期：2003-11-01 00:00:00

  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.

    abstract：:Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain referenc...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404481

    authors： Brüggemann M,White H,Gaulard P,Garcia-Sanz R,Gameiro P,Oeschger S,Jasani B,Ott M,Delsol G,Orfao A,Tiemann M,Herbst H,Langerak AW,Spaargaren M,Moreau E,Groenen PJ,Sambade C,Foroni L,Carter GI,Hummel M,Bastard C,D

    更新日期：2007-02-01 00:00:00

  • Complex landscape of alternative splicing in myeloid neoplasms.

    abstract：:Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-1002-y

    authors： Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

    更新日期：2020-08-04 00:00:00

  • TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

    abstract：:Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0550-5

    authors： Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

    更新日期：2019-11-01 00:00:00

  • The oncogenicity of Jun.

    abstract：:A mutational analysis of the delta region of the Jun protein shows an inverse correlation between transforming and transactivation potential of the mutant proteins if both properties are measured in chicken embryo fibroblasts. The possibility that Jun acquires oncogenicity not by gain but by loss of function is also s...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Vogt PK,Morgan IM,Håvarstein L,Su H,Hartl M,Schuur E

    更新日期：1992-01-01 00:00:00

  • Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.

    abstract：:To determine the clinical relevance of in vitro drug chemoresistance in childhood acute myeloid leukemia, we used an MTT assay to test leukemic cells from 132 newly diagnosed children. Patients were diagnosed according to the French-American-British (FAB) classification as follows: M0 (n = 12), M1 (n = 16), M2 (n = 53...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402305

    authors： Yamada S,Hongo T,Okada S,Watanabe C,Fujii Y,Ohzeki T

    更新日期：2001-12-01 00:00:00

  • Studies of decitabine with allogeneic progenitor cell transplantation.

    abstract：:The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1)....

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Giralt S,Davis M,O'Brien S,van Besien K,Champlin R,de Vos D,Kantarjian H

    更新日期：1997-03-01 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract：:Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.194

    authors： Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期：2013-12-01 00:00:00

  • De novo gene mutations in normal human memory B cells.

    abstract：:In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0289-4

    authors： Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

    更新日期：2019-05-01 00:00:00

  • Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

    abstract：:The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug. However, most patients relapse after withdrawal of imatinib and advanced stage patients often develop drug resistance. As CML is considered a ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404638

    authors： Brendel C,Scharenberg C,Dohse M,Robey RW,Bates SE,Shukla S,Ambudkar SV,Wang Y,Wennemuth G,Burchert A,Boudriot U,Neubauer A

    更新日期：2007-06-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2016.299

    authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期：2017-04-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract：:Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0416-x

    authors： Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期：2019-09-01 00:00:00

  • Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.

    abstract：:Clinical characteristics, treatment response and outcome were evaluated in children with Down's syndrome (DS) and acute lymphoblastic leukemia (ALL) as compared to other children with ALL (NDS). Sixty-one DS and 4049 NDS patients, receiving intensive antileukemic treatment during four consecutive trials (ALL-BFM 81, 8...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400989

    authors： Dördelmann M,Schrappe M,Reiter A,Zimmermann M,Graf N,Schott G,Lampert F,Harbott J,Niemeyer C,Ritter J,Dörffel W,Nessler G,Kühl J,Riehm H

    更新日期：1998-05-01 00:00:00

  • Resistance to cytosine arabinoside in acute leukemia: the significance of mutations in CTP synthetase.

    abstract：:The molecular events which confer cellular resistance to cytotoxic drugs such as cytosine arabinoside (ara-C) are poorly understood. Nevertheless, in a proportion of patients with acute leukemia, such events will be responsible for the failure of therapy. Mutations which cause ara-C resistance in a chinese hamster ova...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Whelan J,Smith T,Phear G,Rohatiner A,Lister A,Meuth M

    更新日期：1994-02-01 00:00:00

  • Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice.

    abstract：:In this study neonatal mice expressing a GM-CSF transgene (GMT mice), and their normal littermate controls, were infected with Moloney murine leukemia virus (MoMLV) to examine in vivo tumorigenesis. By 200 days, all of the GMT mice had died whereas median survival had not been reached in the littermates (P < 0.0003). ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400614

    authors： Rasko JE,Metcalf D,Alexander B,Strasser A,Begley CG

    更新日期：1997-05-01 00:00:00

  • In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia.

    abstract：:Previous studies have indicated that colony-stimulating factors may stimulate myelopoiesis and thus increase the number of circulating white blood cells in patients with hematopoietic failure including aplastic anemia. However, long-term administration of the factor was required to maintain its response. In the presen...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Herrmann F,Lindemann A,Raghavachar A,Heimpel H,Mertelsmann R

    更新日期：1990-10-01 00:00:00

  • Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

    abstract：:In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent prognostic information. However, data on the value of earlier flow MRD assessment are lacking. Therefore, the value of flow MRD dete...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.186

    authors： Köhnke T,Sauter D,Ringel K,Hoster E,Laubender RP,Hubmann M,Bohlander SK,Kakadia PM,Schneider S,Dufour A,Sauerland MC,Berdel WE,Büchner T,Wörmann B,Braess J,Hiddemann W,Spiekermann K,Subklewe M

    更新日期：2015-02-01 00:00:00

  • CLL family 'Pedigree 14' revisited: 1947-2004.

    abstract：:The notion that inherited predisposition contributes to the development of haematological malignancies is generally thought of as being a relatively new idea. However, Videbaek made a clear enunciation of such a hypothesis in 1947, from a study of tumour incidence in relatives of patients with different leukaemias. To...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403727

    authors： Jønsson V,Houlston RS,Catovsky D,Yuille MR,Hilden J,Olsen JH,Fajber M,Brandt B,Sellick G,Allinson R,Wiik A

    更新日期：2005-06-01 00:00:00